146 related articles for article (PubMed ID: 37949378)
1. Comparative analysis of Basiliximab and Alemtuzumab induction therapies in blood type A2-to-B kidney transplantation: Impact on kidney function and de novo donor-specific HLA antibodies.
Hanouneh T; Attieh RM; Craver E; Jebrini A; Elrefaei M; Jarmi T
Transpl Immunol; 2023 Dec; 81():101958. PubMed ID: 37949378
[TBL] [Abstract][Full Text] [Related]
2. Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
Jarmi T; Abdelmoneim Y; Li Z; Jebrini A; Elrefaei M
Transpl Immunol; 2023 Apr; 77():101778. PubMed ID: 36584928
[TBL] [Abstract][Full Text] [Related]
3. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience.
Yakubu I; Ravichandran B; Sparkes T; Barth RN; Haririan A; Masters B
J Pharm Pract; 2021 Apr; 34(2):199-206. PubMed ID: 31315501
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
[TBL] [Abstract][Full Text] [Related]
7. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
; Haynes R; Harden P; Judge P; Blackwell L; Emberson J; Landray MJ; Baigent C; Friend PJ
Lancet; 2014 Nov; 384(9955):1684-90. PubMed ID: 25078310
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
10. Tailored immunosuppression after kidney transplantation - a single center real-life experience.
Good-Weber M; Roos M; Mueller TF; Rüsi B; Fehr T
BMC Nephrol; 2020 Nov; 21(1):501. PubMed ID: 33228545
[TBL] [Abstract][Full Text] [Related]
11. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
12. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.
Brokhof MM; Sollinger HW; Hager DR; Muth BL; Pirsch JD; Fernandez LA; Bellingham JM; Mezrich JD; Foley DP; D'Alessandro AM; Odorico JS; Mohamed MA; Vidyasagar V; Ellis TM; Kaufman DB; Djamali A
Transplantation; 2014 Mar; 97(6):612-7. PubMed ID: 24531846
[TBL] [Abstract][Full Text] [Related]
13. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.
Todeschini M; Cortinovis M; Perico N; Poli F; Innocente A; Cavinato RA; Gotti E; Ruggenenti P; Gaspari F; Noris M; Remuzzi G; Casiraghi F
J Immunol; 2013 Sep; 191(5):2818-28. PubMed ID: 23913968
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
[TBL] [Abstract][Full Text] [Related]
15. Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience.
Florescu DF; Seaman JA; Kalil AC; Qiu F; Bremers D; Westphal SG
Transplant Proc; 2021 Apr; 53(3):1058-1063. PubMed ID: 32921434
[TBL] [Abstract][Full Text] [Related]
16. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens.
Aydin-Ghormoz E; Ortiz J; Koizumi N; Li MH; Faddoul G
Pediatr Transplant; 2024 Jun; 28(4):e14783. PubMed ID: 38767019
[TBL] [Abstract][Full Text] [Related]
18. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
[TBL] [Abstract][Full Text] [Related]
19. Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience.
Furukawa M; Chan EG; Ryan JP; Hyzny EJ; Sacha LM; Coster JN; Pilewski JM; Lendermon EA; Kilaru SD; McDyer JF; Sanchez PG
Front Immunol; 2022; 13():864545. PubMed ID: 35720296
[TBL] [Abstract][Full Text] [Related]
20. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]